Abstract: Cannabinoid receptors are widely distributed in the nuclei of the extrapyramidal motor and mesolimbic reward systems; their exact functions are, however, not known. The aim of the present study was to characterize the effects of cannabinoids on the electrically evoked release of endogenous dopamine in the corpus striatum and the nucleus accumbens. In rat brain slices dopamine release elicited by single electrical pulses was determined by fast cyclic voltammetry. Dopamine release was markedly inhibited by the OP 2 opioid receptor agonist U-50488 and the D 2 /D 3 dopamine receptor agonist quinpirole, indicating that our method is suitable for studying presynaptic modulation of dopamine release. In contrast, the CB 1 /CB 2 cannabinoid receptor agonists WIN55212-2 (10 Ϫ6 M) and CP55940 (10
The primary molecular targets of the active components of marijuana and hashish are the cannabinoid receptors. Two G protein-coupled receptors have been identified, the CB 1 and CB 2 cannabinoid receptors; the CB 1 receptor is preferentially located on neurons, whereas the CB 2 receptor occurs mainly on peripheral nonneuronal cells (for review, see Howlett, 1995; Compton et al., 1996; Pertwee, 1997) .
The distribution of cannabinoid receptors in the CNS is well characterized (Herkenham et al., 1991; Jansen et al., 1992; Mailleux and Vanderhaeghen, 1992; Romero et al., 1997; Tsou et al., 1998) . Moderate to high concentrations were observed in practically all regions belonging to the extrapyramidal motor system, e.g., corpus striatum, substantia nigra, globus pallidus, entopeduncular nucleus, and subthalamic nucleus, and the mesolimbic reward system, e.g., nucleus accumbens and ventral tegmental area. Accordingly, cannabinoids can markedly affect the function of these systems, producing catalepsy and rewarding effects (Howlett, 1995; Compton et al., 1996; Tanda et al., 1997; Martellotta et al., 1998) . The exact mechanisms of these effects-how functions of identified neurons of the extrapyramidal motor and mesolimbic reward systems are influenced-are not known.
It was recently reported that cannabinoids inhibit the electrically evoked release of previously incorporated [ 3 H]dopamine from slices of rat striatum (Cadogan et al., 1997) . The aim of the present experiments was to characterize the effects of cannabinoids on the electrically evoked release of endogenous dopamine in the rat dorsal striatum and nucleus accumbens. We studied the effects of two synthetic mixed CB 1 /CB 2 cannabinoid receptor agonists: WIN55212-2 (an aminoalkylindole) and CP55940 (a bicyclic compound structurally resembling ⌬ 9 -tetrahydrocannabinol). The cannabinoids were compared with two established presynaptic modulators of dopamine release: the OP 2 opioid receptor (previously called -opioid receptor) agonist U-50488 and the D 2 /D 3 dopamine receptor agonist quinpirole.
MATERIALS AND METHODS

Preparation and superfusion of brain slices
The experiments were approved by a government ethical committee on animal experiments. Adult male Wistar rats (weighing 250 -330 g) were anesthetized with diethylether and decapitated. The brains were submerged in ice-cold artificial CSF (ACSF) containing 118 mM NaCl, 25 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 4.8 mM KCl, 1.2 mM MgSO 4 , 2 mM CaCl 2 , 11 mM glucose, and 0.03 mM Na 2 EDTA (gassed with 95% O 2 /5% CO 2 ). Brain slices, 350 m thick, were cut using a vibrating tissue slicer (Vibratom 3000; Plano, Wetzlar, Germany). The slices were transferred to a Perspex superfusion chamber and superfused at a rate of 0.8 ml/min at 34°C with ACSF containing 0.001 mM nomifensine (to block neuronal reuptake of dopamine). For recording dorsal striatal dopamine release, coronal slices 0.2-1.7 mm rostral to the bregma were used, and the working electrode was positioned in the dorsolateral region of the striatum. For recording dopamine release in the nucleus accumbens, coronal slices 1.7-2.2 mm rostral to the bregma were used, and the working electrode was positioned ventromedial to the anterior comissure.
Voltammetry
The concentration of endogenous dopamine in the brain slice was determined with fast cyclic voltammetry as described by Stamford (1995) and Limberger et al. (1991) . In brief, a carbon fiber working electrode (tip diameter, 8 m) was inserted into the slice, with the tip lying 50 -100 m below the surface. A voltammetric analyzer (Millar voltammetric analyzer; P.D. Systems, West Molesey, Surrey, U.K) delivered a W-form voltage to the electrode every 0.25 s, recorded the resulting current, and evaluated the dopamine oxidation current at 0.60 V. Dopamine release was elicited by a bipolar tungsten electrode placed within 200 m of the working electrode; single rectangular electrical pulses (100 s, 20 V) were generated by an isolated stimulator (Digitimer DS2; Welwyn Garden City, Herts, U.K.). In our laboratory, single-pulse electrical stimulation under the above experimental conditions increases the dopamine concentration in slices of corpus striatum and nucleus accumbens by 1.3 and 1 M, respectively (Limberger et al., 1991) . In the present experiments, stimulation-evoked absolute increases in dopamine concentration were not regularly determined; dopamine release values during superfusion of drugs were expressed as percentages of initial reference values (see Evaluation and statistics).
Protocol
Electrical stimulation was started after 60 min of superfusion; single electrical pulses were delivered every 2 min until the end of the experiments. Stable responses to stimulation were reached 60 -90 min after the beginning of stimulation, and this time is defined as t ϭ 0 min in the subsequent text and in the figures. Figure 1 shows a typical original tracing.
The first eight pulses (P1-P8; at t ϭ 0, 2, . . . 14 min) were taken as initial reference (PRE) values. After the PRE interval, drugs were superfused for different periods, as indicated in the figures. Tetrodotoxin, tetraethylammonium, Ca 2ϩ -free medium, and SR141716A were superfused for 16 min. Increasing concentrations of U-50488 and quinpirole were superfused for 16-min (corpus striatum) or 32-min (nucleus accumbens) periods. WIN55212-2 and CP55940 were superfused for 60 min. In control experiments different solvents were superfused after PRE: standard ACSF, ACSF containing 1 ml/L dimethyl sulfoxide and 1 g/L bovine serum albumin, ACSF containing 10 ml/L 1,2-propanediol, and ACSF containing 0.75 mg/L Tween 80.
Evaluation and statistics
In each experiment, the eight initial values (P1-P8) were averaged (PRE); all values of an experiment were expressed as percentages of PRE. Data are given as mean Ϯ SEM values throughout. Statistical differences between groups were evaluated with the nonparametric two-tailed Mann-Whitney test; in the case of multiple comparisons with the same control group, the Bonferroni correction was used. The limit of significance was defined as p Ͻ 0.05, and only this value is shown, even if p Ͻ 0.01 or 0.001.
Drugs
Drugs were obtained from the following sources:
benzeneacetamide HCl (U-50488) from Research Biochemicals International (Köln, Germany); and fatty acid free bovine serum albumin, tetraethylammonium chloride, tetrodotoxin, and Tween 80 from Sigma (Deisenhofen, Germany).
For most experiments, WIN55212-2, CP55940, and SR141716A were dissolved in dimethyl sulfoxide and stored at Ϫ20°C; further dilutions were made with ACSF containing 1 g/L fatty acid free bovine serum albumin (the latter was used to keep cannabinoids in solution and to prevent adsorption to superfusion tubing and chamber). The final concentration of FIG. 1. Effects of tetrodotoxin (TTX) and zero calcium concentration on electrically evoked release of dopamine in corpus striatum. The slice was stimulated with single electrical pulses every 2 min. The first eight pulses (P1-P8) were taken as initial reference values (PRE). ACSF containing TTX (3 ϫ 10 Ϫ7 M) and ACSF in which the Ca 2ϩ concentration was 0 mM were superfused for 16 min. Dopamine concentration is shown in arbitrary units.
dimethyl sulfoxide in the ACSF was 1 ml/L. In one series of experiments, WIN55212-2 was dissolved in 1,2-propanediol and stored at Ϫ20°C; further dilutions were made with ACSF. The final concentration of 1,2-propanediol in the ACSF was 10 ml/L. In one series of experiments, CP55940 was dissolved in ethanol and stored at Ϫ20°C; further dilutions were made using Tween 80 and ACSF (ethanol was evaporated), as described by Pertwee et al. (1992) . The final concentration of Tween 80 in the ACSF was 0.75 mg/L. Tetrodotoxin, U-50488, and quinpirole were dissolved in distilled water and then further diluted with ACSF. Tertraethylammonium was dissolved in ACSF.
RESULTS
Corpus striatum
There were four control groups. One group of slices was superfused with standard ACSF (Fig. 2 , upper panel). A second group was superfused with ACSF containing dimethyl sulfoxide and bovine serum albumin after PRE (Fig. 2, middle panel) . A third group was superfused with ACSF containing 1,2-propanediol after PRE (data not shown). The fourth control group was superfused with ACSF containing Tween 80 after PRE (Fig. 2,  lower panel) . In all four control groups, the electrically evoked dopamine release remained fairly constant during the course of the experiments.
The electrically evoked dopamine release was abolished by an inhibitor of voltage-dependent sodium channels, tetrodotoxin (see Fig. 1 for an original tracing): 16 min after the beginning of superfusion with tetrodotoxin (3 ϫ 10 Ϫ7 M), dopamine release was 8 Ϯ 4% of PRE (n ϭ 10; p Ͻ 0.05). Superfusion with Ca 2ϩ -free ACSF also caused marked inhibition (see Fig. 1 for an original tracing): 16 min after the beginning of superfusion with Ca 2ϩ -free ACSF, dopamine release was 11 Ϯ 8% of PRE (n ϭ 5; p Ͻ 0.05). The OP 2 opioid receptor agonist U-50488 (10 Ϫ9 -10 Ϫ6 M) and the D 2 /D 3 dopamine receptor agonist quinpirole (10 Ϫ8 -10 Ϫ6 M) caused concentration-dependent inhibition of dopamine release (Fig. 2,  upper panel) .
The mixed CB 1 /CB 2 cannabinoid receptor agonist WIN55212-2 was dissolved in dimethyl sulfoxide and further diluted in ACSF containing bovine serum albumin. WIN55212-2 (10 Ϫ6 M), superfused for 60 min, had no effect on the electrically evoked dopamine release (Fig. 2, middle panel) . In another series of experiments, WIN55212-2 was dissolved in 1,2-propanediol and further diluted in ACSF. WIN55212-2 (10 Ϫ6 M) had no effect on dopamine release also with this solvent: 60 min after the beginning of superfusion of WIN55212-2, the dopamine release was 108 Ϯ 10% of PRE (n ϭ 6), not significantly different from the corresponding solvent group, in which dopamine release was 109 Ϯ 8% of PRE (n ϭ 9; p Ͼ 0.05). The other mixed CB 1 /CB 2 cannabinoid receptor agonist, CP55940, was dissolved in ethanol and further diluted in ACSF containing Tween 80. CP55940 (10 Ϫ6 M), superfused for 60 min, had no effect on the electrically evoked release of dopamine (Fig. 2,  lower panel) .
Nucleus accumbens
There were two control groups. One group of slices was superfused with standard ACSF (Fig. 3) . The second group of slices was superfused with ACSF containing 1 ml/L dimethyl sulfoxide and 1 g/L bovine serum albumin after PRE (Fig. 4) . In both control groups, the electrically evoked dopamine release remained constant during the course of the experiments.
The electrically evoked dopamine release was again abolished by tetrodotoxin: 16 min after the beginning of superfusion with tetrodotoxin (3 ϫ 10 Ϫ7 M), dopamine release was 1 Ϯ 1% of PRE (n ϭ 4; p Ͻ 0.05; data not shown). Superfusion of Ca 2ϩ -free ACSF for 16 min also caused marked inhibition: Dopamine release decreased to 4 Ϯ 2% of PRE (n ϭ 3; p Ͻ 0.05; data not shown). The OP 2 opioid receptor agonist U-50488 (10 Ϫ7 -10 Ϫ5 M) caused concentration-dependent inhibition of dopamine release (Fig. 3, upper panel) . The potassium channel blocker tetraethylammonium (10 Ϫ2 M) caused a
FIG. 2. Effects of solvent (SOL)
, U-50488, quinpirole, WIN55212-2, and CP55940 on electrically evoked release of dopamine (DA) in corpus striatum. Upper panel: After an initial period (PRE), increasing concentrations of U-50488 (n ϭ 7) and quinpirole (n ϭ 7) were superfused, with each concentration for 16 min. The third group received SOL (ACSF; n ϭ 11) after PRE. Middle panel: WIN55212-2 (10 Ϫ6 M; n ϭ 6) or SOL (containing dimethyl sulfoxide and bovine serum albumin; n ϭ 11) was superfused for 60 min after PRE. Lower panel: CP55940 (10 Ϫ6 M; n ϭ 8) or SOL (containing Tween 80; n ϭ 9) was superfused for 60 min after PRE. Values are expressed as percentages of PRE. Data are mean Ϯ SEM (bars) values. *p Ͻ 0.05, significant difference from the appropriate SOL group. The arrows indicate that the differences were significant at all further points. more than twofold increase in dopamine release (Fig. 3,  lower panel) .
The mixed CB 1 /CB 2 cannabinoid receptor agonists WIN55212-2 and CP55940 were dissolved in dimethyl sulfoxide and further diluted with ACSF containing bovine serum albumin. WIN55212-2 (10 Ϫ6 M), superfused for 60 min, had no effect on the electrically evoked dopamine release (Fig. 4, upper panel) . CP55940 also had no major effect on dopamine release (Fig. 4, middle  panel) . The decrease observed at the end of the 60-min superfusion of CP55940 (10 Ϫ6 M) is probably accidental, because at the higher concentration (10 Ϫ5 M) CP55940 did not elicit any effect. Figure 4 (lower panel) shows the results of experiments in which the CB 1 cannabinoid receptor antagonist SR141716A (10 Ϫ6 M) was superfused: The electrically evoked dopamine release was not changed.
Lack of effect of cannabinoids on voltammetric measurement of dopamine
In experiments with striatal and accumbens slices, WIN55212-2 (10 Ϫ6 M) and CP55940 (10 Ϫ6 M) did not change the baseline voltammetric signal (data not shown), indicating that these drugs are not oxidized at the potential selected to measure dopamine (0.6 V). In a slice-free superfusion chamber, dopamine at 10 Ϫ7 , 3.3 ϫ 10 Ϫ7 , and 10 Ϫ6 M elicited oxidation currents having an amplitude of 2.7 Ϯ 1.3, 6.7 Ϯ 2.3, and 13.0 Ϯ 4.2 A (n ϭ 8), respectively. The dopamine-evoked currents were very similar in the presence of WIN55212-2 (10 Ϫ6 M), 2.8 Ϯ 1.6, 6.6 Ϯ 3.4, and 13.0 Ϯ 6.5 A (n ϭ 6), respectively, as well as in the presence of CP55940 (10 Ϫ6 M), 2.5 Ϯ 1.7, 8.2 Ϯ 0.3, and 14.2 Ϯ 1.5 A (n ϭ 6), respectively. Thus, WIN55212-2 and CP55940 did not change the response of the working electrode to dopamine.
DISCUSSION
Tetrodotoxin and superfusion of calcium-free medium inhibited dopamine release, indicating that the electrical stimulation produced action potential-dependent, quasiphysiological release of endogenous dopamine from axon terminals of nigrostriatal and mesolimbic dopaminergic neurons. The perikarya of these neurons in the pars compacta of the substantia nigra and in the ventral tegmental area produce mRNA for OP 2 opioid receptors and D 2 and D 3 dopamine receptors, and part of the   FIG. 4 . Effects of solvent (SOL), WIN55212-2, CP55940, and SR141716A on electrically evoked release of dopamine in nucleus accumbens. Upper panel: After an initial period (PRE), WIN55212-2 (10 Ϫ6 M; n ϭ 8) or SOL (containing dimethyl sulfoxide and bovine serum albumin; n ϭ 10) was superfused for 60 min. Middle panel: CP55940 (10 Ϫ6 M; n ϭ 7), CP55940 (10 Ϫ5 M; n ϭ 6) or solvent (containing dimethyl sulfoxide and bovine serum albumin; n ϭ 10) was superfused for 60 min after PRE. Lower panel: SR141716A (10 Ϫ6 M; n ϭ 6) or SOL (containing dimethyl sulfoxide and bovine serum albumin; n ϭ 10) was superfused for 16 min after PRE. Values are expressed as percentages of PRE. Data are mean Ϯ SEM (bars) values. *p Ͻ 0.05, significant difference from the SOL group.
FIG. 3.
Effects of solvent (SOL), U-50488, and tetraethylammonium (TEA) on electrically evoked release of dopamine (DA) in nucleus accumbens. Upper panel: After an initial period (PRE), increasing concentrations of U-50488 (n ϭ 8) were superfused, with each concentration for 32 min. The second group received SOL (ACSF; n ϭ 6) after PRE. Lower panel: TEA (10 Ϫ2 M; n ϭ 6) or SOL (ACSF; n ϭ 6) was superfused for 16 min after PRE. Values are expressed as percentages of the PRE. Data are mean Ϯ SEM (bars) values. *p Ͻ 0.05, significant difference from the SOL group. The arrow indicates that differences were significant at all further points.
synthesized receptors is transported into the axon terminals in the corpus striatum and nucleus accumbens (Fallon and Loughlin, 1995; Mansour et al., 1995; Healy and Meador-Woodruff, 1996; Suzuki et al., 1998) . Inhibition of electrically evoked dopamine release by U-50488 and quinpirole in the present experiments is due to activation of these presynaptic receptors at the axon terminals. The results confirm previous observations of presynaptic inhibition of dopamine release by OP 2 and D 2 /D 3 receptor agonists in the corpus striatum and nucleus accumbens (Starke et al., 1989; Heijna et al., 1990; Bull and Sheehan, 1991; Mulder et al., 1991) and show that the voltammetry as used by us is suitable for studying presynaptic inhibition of dopamine release in these nuclei. The nonselective potassium channel blocker tetraethylammonium caused a marked increase in transmitter release in the nucleus accumbens, indicating that our model is also suitable for studying facilitatory effects on electrically evoked dopamine release.
WIN55212-2 and CP55940 are synthetic cannabinoids belonging to different chemical classes. They possess high affinity for CB 1 and CB 2 cannabinoid receptors in radioligand binding and functional studies [as a rule, K i and IC 50 Ͻ 30 nM (Kuster et al., 1993; Felder et al., 1995; Showalter et al., 1996) ]. The 1 mol/L concentration of WIN55212-2 and CP55940 used in the present experiments was thus more than 30-fold higher than the dissociation constants of these drugs for CB 1 and CB 2 cannabinoid receptors. We used several solvents for dissolving and keeping in solution the cannabinoids (dimethyl sulfoxide combined with bovine serum albumin, 1,2-propanediol, and Tween 80) but did not observe a cannabinoid effect under any condition. Combined with these solvents, WIN55212-2 and CP55940 (Յ1 mol/L) elicit effects in appropriate isolated tissue preparations (see, e.g., Schlicker et al., 1996; Pertwee and Fernando, 1996) , including brain slices . In the nucleus accumbens, the CB 1 cannabinoid receptor antagonist SR141716A failed to influence the dopamine release. The possibility can thus be excluded that an endogenous cannabinoid is active under our experimental conditions and reduces the potential of exogenous agonists for eliciting an effect. The remaining and likely explanation for our inability to observe an inhibition of dopamine release by WIN55212-2 and CP55940 is that presynaptic CB 1 or CB 2 cannabinoid receptors are not present on axon terminals of nigrostriatal and mesolimbic dopaminergic neurons. Neuroanatomical findings support this conclusion. No or a very low level of CB 1 cannabinoid receptor mRNA is observed in the substantia nigra pars compacta and the ventral tegmental area (Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1993; Romero et al., 1997) ; therefore, it is unlikely that the axon terminals of nigrostriatal and mesolimbic dopaminergic neurons contain presynaptic CB 1 cannabinoid receptors. A similar conclusion was drawn in another study in which neuron lesion techniques were used (Herkenham et al., 1991) . In this latter study, it was suggested that most striatal CB 1 cannabinoid receptors are localized on GABAergic medium spiny neurons; the activation of these receptors inhibits GABAergic neurotransmission between terminals of recurrent axons of medium spiny neurons and medium spiny neurons themselves .
As mentioned in the introductory section, Cadogan et al. (1997) observed an inhibition of electrically evoked [ 3 H]dopamine release by CP55940 (1 M) and anandamide (10 M) in the corpus striatum. We can only speculate on the reason for this discrepancy. Electrical stimulation of striatal slices can evoke dopamine release not only by direct activation of dopaminergic axons; excitatory neurons can also be activated, and the released excitatory amino acids can in turn elicit dopamine release (see Jin and Fredholm, 1997) . In our experiments, very moderate electrical stimulation (100-s-wide pulses, 20 V voltage, single pulses every 2 min) is used to elicit dopamine release. Glutamate is not involved in the release of dopamine elicited by this stimulation: Combined application of an NMDA receptor antagonist (DL-2-aminophosphonopentanoic acid at 2 ϫ 10 Ϫ4 M) and a non-NMDA receptor antagonist (6-cyano-7-nitroquinoxaline-2,3-dione at 10 Ϫ5 M) does not change the release of dopamine (T.M. and B.Sz., unpublished data). It may be that under the condition of the more intensive stimulation used by Cadogan et al. (1997) (5-ms-wide pulses, 100 mA current strength, 90 pulses at 0.5 Hz), the indirect glutamatergic mechanism of dopamine release operated and that cannabinoids primarily inhibited the release of glutamate. It should also be noted that it was not verified in the experiments of Cadogan et al. (1997) that [ 3 H]dopamine was released from dopaminergic axon terminals in an action potential-dependent, quasiphysiological fashion. Whatever the explanation for the discrepancy, we point out again that the anatomical distribution of cannabinoid receptors is in accord with our findings.
As mentioned in the introductory section, cannabinoids cause catalepsy in experimental animals. Presynaptic inhibition of dopamine release in the striatum from nigrostriatal neurons could explain this motor disturbance. However, as shown here, such an inhibition does not occur. Humans use cannabis products mainly for their euphoric effects, effects most likely mediated by the mesolimbic dopaminergic system. It was recently shown that systemically administered cannabinoids enhance the release of dopamine in the nucleus accumbens and that this effect is due to an enhanced firing of mesolimbic dopaminergic neurons (Tanda et al., 1997; Gessa et al., 1998) . The results of the present study indicate that the dopamine release in the nucleus accumbens is not additionally modified by a presynaptic mechanism.
